Phase III data on Incruse Ellipta plus Breo Ellipta show benefits in COPD - GSK/Theravance
GlaxoSmithKline and Theravance have announced positive results from two Phase III studies, which showed that patients with Chronic Obstructive Pulmonary Disease (COPD) who received Incruse Ellipta (umeclidinium (UMEC) 62.5mcg), or umeclidinium 125mcg (an unlicensed dose) in addition to Relvar/Breo Ellipta (fluticasone furoate/vilanterol, �FF/VI�) achieved an additional improvement in lung function (FEV1) compared to patients receiving FF/VI plus placebo.
The studies showed that for the primary endpoint of trough FEV1 at Day 85, the addition of UMEC 62.5mcg or UMEC 125mcg to FF/VI 100/25mcg resulted in a statistically significant improvement in lung function when compared with FF/VI 100/25mcg plus placebo in patients with COPD. These studies are the first to investigate the combined effect of the two medicines, both of which provide 24 hour efficacy. The full results of these studies will be presented at a future scientific meeting.
530 mins
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.